Similarly, the administration of competitive inhibitors of BACE1 improves outcomes in animal models of Alzheimer’s disease and provides the rationale for extending this treatment to patients (Vassar et al. 2014). The gene discussed is BACE1; the disease is early-onset autosomal dominant Alzheimer disease.